Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 16

recruiting
3 968
countries
28
conditions
2 103

10 282 trials match your criteria

Herpes zoster

Recruiting

Non‑inferiority of fractional varicella zoster virus glycoprotein E vaccine (AS01B) versus recombinant varicella zoster virus glycoprotein E vaccine in adults with shingles

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Recombinant Varicella Zoster Virus Glycoprotein E

Influenza+1

Recruiting

Efficacy and safety of the investigational mRNA influenza vaccine gskvx000000077430 (drug combination) in adults ≥ 65 years

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:65+ years · Healthy volunteers
  • Substances:INFLUENZA A VIRUS, A/CROATIA/10136RV/2023 (H3N2) LIKE STRAIN X-425A, INACTIVATED

Transitional cell carcinoma

Recruiting

Adjuvant Datopotamab Deruxtecan with Drug Combination in Patients with High‑Risk Muscle‑Invasive Urothelial Carcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Durvalumab

Conjunctivitis allergic+1

Recruiting

Efficacy of Tree SLIT-tablet and Betula pendula pollen extract in adolescents (12‑17) with allergic rhinitis/rhinoconjunctivitis caused by birch pollen

Investigational
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Betula Pendula Pollen Extract

Obesity

Recruiting

Long‑term Efficacy, Safety and Tolerability of maridebart cafraglutide in Adults with Obesity and Type 2 Diabetes

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide

Ovarian cancer recurrent

Recruiting

Rinatabart Sesutecan with or without bevacizumab versus standard platinum‑based chemotherapy drug combination in patients with recurrent platinum‑sensitive ovarian cancer

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab

Chronic obstructive pulmonary disease

Recruiting

Study of Brenipatide (LY3537031) in Adults with Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:LY3537031

Obesity+1

Recruiting

A Phase 3 Study of Once‑Monthly PF‑08653944 vs Placebo for Weight Loss in Adults with Overweight or Obesity

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years

Small cell lung cancer extensive stage

Recruiting

Phase 3 Study of Subcutaneous vs Intravenous Tarlatamab with Siltuximab in Relapsed Extensive-Stage Small Cell Lung Cancer after Platinum Chemotherapy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Siltuximab

Non-small cell lung cancer metastatic

Recruiting

Phase 2 Study of Imzokitug with drug combination as First‑Line Treatment for Adults with Locally Advanced or Metastatic Non‑Small Cell Lung Cancer (NSCLC)

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bms-986340

Tardive dyskinesia

Recruiting

Efficacy, Safety, and Tolerability of NBI-1065890 in Adults with Tardive Dyskinesia

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years

Dermatitis atopic

Recruiting

Pharmacokinetics, Safety and Efficacy of Nemolizumab in Infants 6–23 Months with Moderate-to-Severe Atopic Dermatitis

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Nemolizumab

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.